Column Group (NASDAQ: TNYA) to sell 657,627 Tenaya shares

Rhea-AI Filing Summary

Tenaya Therapeutics shareholder Column Group III, LP has filed to sell up to 657,627 shares of common stock under Rule 144. The planned sale is to be executed through BTIG, LLC on NASDAQ, with an approximate sale date of 02/11/2026 and an aggregate market value of $446,989.00.

The shares were originally acquired on 07/31/2017 in a Series A financing for cash. Column Group III, LP also sold 161,422 Tenaya common shares on 02/10/2026 for gross proceeds of $131,736.49. Shares outstanding were 213,744,535 common shares at the time referenced.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	BTIG, LLC 350 Bush Street 9th Floor San Francisco CA 94104	657627	446989.00	213744535	02/11/2026	NASDAQ GS

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/31/2017	Series A financing	Tenaya Therapeutics			657627	07/31/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
COLUMN GROUP III, LP 1 Letterman Drive Suite DM-900 San Francisco CA 94129	Common	02/10/2026	161422	131736.49

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Tenaya Therapeutics (TNYA) disclose?

The Form 144 shows Column Group III, LP plans to sell up to 657,627 Tenaya Therapeutics common shares through BTIG on NASDAQ. The filing outlines share amounts, approximate sale date, market value, past three-month sales, and how the shares were originally acquired in a Series A financing.

How many Tenaya Therapeutics (TNYA) shares are planned for sale in this notice?

The notice covers a proposed sale of 657,627 shares of Tenaya Therapeutics common stock. These shares are to be sold through BTIG, LLC on NASDAQ, with an aggregate market value stated as $446,989.00 based on the information in the filing’s securities table.

Who is selling Tenaya Therapeutics (TNYA) shares according to this Form 144?

The seller is Column Group III, LP, listed as the entity for whose account Tenaya Therapeutics shares are to be sold. The filing details its planned sale of 657,627 common shares and notes an additional sale of 161,422 shares completed on 02/10/2026 with specified gross proceeds.

When were the Tenaya Therapeutics (TNYA) shares being sold originally acquired?

The 657,627 Tenaya Therapeutics common shares were acquired on 07/31/2017 in a Series A financing transaction. The filing states the acquisition was made for cash on that same date, providing a clear history of when and how these securities were obtained before the planned Rule 144 sale.

What recent Tenaya Therapeutics (TNYA) share sales are reported in the past three months?

The document reports that Column Group III, LP sold 161,422 Tenaya Therapeutics common shares on 02/10/2026. These shares generated gross proceeds of $131,736.49. This prior sale is disclosed alongside the new planned sale of 657,627 shares under Rule 144 in the same notice.

How many Tenaya Therapeutics (TNYA) shares were outstanding at the time referenced?

The filing notes that 213,744,535 Tenaya Therapeutics common shares were outstanding. This figure appears in the securities information table and serves as a baseline context for the size of the planned 657,627-share sale relative to the company’s total common shares outstanding at that time.